Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
The American Journal of Gastroenterology|February 9, 2021
Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus InfectionGrace Lai-Hung Wong, Vincent Wai-Sun Wong, Vicki Wing-Ki Hui, et al.
Cancer Medicine|August 12, 2020
Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort studyStephen Lam Chan, Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 7, 2025
Overcoming immunotherapy resistance in hepatocellular carcinoma by targeting myeloid IL-8/CXCR2 signalingTsz Tung Kwong, Zhewen Xiong, Yiling Zhang, et al.
Hepatology (Baltimore, Md.)|July 5, 2022
Age and the relative importance of liver-related deaths in nonalcoholic fatty liver diseaseHuapeng Lin, Terry Cheuk-Fung Yip, Xinrong Zhang, et al.
Liver Cancer|September 26, 2022
Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Gemcitabine plus Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical TrialStephen Lam Chan, Chanisa Chotipanich, Su Pin Choo, et al.
Therapeutic Advances in Medical Oncology|October 7, 2021
ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240Arndt Vogel, Philippe Merle, Chris Verslype, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriersVincent Wai-Sun Wong, Stephen Lam Chan, Frankie Mo, et al.
Hepatology (Baltimore, Md.)|April 29, 2023
Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysisXinrong Zhang, Terry Cheuk-Fung Yip, Yee-Kit Tse, et al.
The American Journal of Gastroenterology|March 10, 2020
Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver DiseaseTing Ting Chan, Wah Kheong Chan, Grace Lai-Hung Wong, et al.
Liver Cancer|January 26, 2026
Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor PrognosisStephen Lam Chan, Masatoshi Kudo, Bruno Sangro, et al.
Pageof 7